Creative Commons source reading · Performance analysis and forecasting
Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential
Christer Malm; Michael Svensson
Originally published in Front Sports Act Living · 2026-06-09
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Meldonium has attracted considerable attention in sports due to its suggested effects on energy metabolism and high-profile doping cases. This narrative review evaluates Meldonium's biochemical mechanisms, pharmacokinetics, safety profile, and the quality of evidence surrounding its use in athletes. While Western literature categorizes Meldonium as a metabolic modulator, Eastern literature often classifies it as an antihypoxic agent. By inhibiting carnitine biosynthesis, Meldonium shifts substrate utilization from fatty acid oxidation toward more oxygen-efficient glucose metabolism. However, despite its widespread use and inclusion on the World Anti-Doping Agency (WADA) prohibited list, there remains a profound lack of high-quality, randomized placebo-controlled trials demonstrating consistent ergogenic benefits in healthy athletes.…
Athletic implications and controversies
While regular moderate exercise is generally cardioprotective, chronic high-intensity training may promote irreversible mitochondrial dysfunction, impaired ATP synthesis, and systemic inflammation (25, 31, 53). Meldonium's reported ability to reduce lactate production, limit ischemic injury, and enhance myocardial recovery has been interpreted as offering a potential performance advantage (32, 38, 39). Such a mechanism seems unlikely to add any major benefit in healthy, highly trained athletes, who already display near-maximal PDH activation and finely tuned regulation of glycolytic flux under heavy exercise. Some data suggest improved blood flow and tissue perfusion, potentially via nitric-oxide–mediated vasodilation, although effects on skeletal-muscle angiogenesis remain speculative (18, 26, 54).
Mechanistic implications for endurance athletes
Inhibiting mitochondrial fatty-acid uptake acutely forces a greater reliance on glucose and glycogen during exercise. For endurance athletes, this can be distinctly disadvantageous: accelerated glycogen depletion may precipitate earlier fatigue and reduce sustained performance within a single session, particularly before any long-term adaptations can occur. While chronic exposure might partially normalize lipid oxidation via changes in gene expression and mitochondrial remodeling, the short-term effect is logically a decrease in exercise tolerance and potentially prolonged recovery. These substrate-use trade-offs highlight the critical need for human studies that address both performance and long-term safety outcomes (including hepatic and renal function) when using fatty-acid oxidation inhibitors.
Editorial reading guide
- How did the authors define training exposure and performance response?
- What alternative explanations, confounders or individual differences limit the conclusion?
